
Ethics Committee Ref	Project Title	Project Site R&D Submission	Date of First Patient Consented	Benchmark Met or Reason for Delay
	·			·
12/SC/0502	Pfizer B1181003 Clinical Study of RN6G (PF-04382923)	28/03/2013		Reasons for delay rest with the Sponsor
12 //11/0021	NACI 10C F1F Futoncion Study Fugly sting Coloction	10/04/2012		Delays due to external factors outside the
13/YH/0021 06/Q1603/07	MCI-196-E15 Extension Study Evaluating Colestilan ChOPIN	10/04/2013 19/04/2013		control of the Sponsor and Trust Benchmark met
06/Q1603/07	Detection of Coagulopathy in Paediatric Heart Surgery	19/04/2013	29/05/2015	benchmark met
13/LO/0504	(DECISION)	10/04/2013	30/04/2013	Benchmark met
12/SC/0515	'Breathe'	24/04/2013	04/11/2013	Reasons for delay rest with the Sponsor
		. ,	, ,	Delays due to external factors outside the
12/EE/0271	SIOP CNS GCT II	24/04/2013		control of the Sponsor and Trust
	NCRN398 IMAGE: Observational Study in Patients with			Reasons for delay rest with both sponsor
12/WA/0058	Unresectable or Metastatic Melanoma	13/05/2013		
12/LO/1361	Cardioprotection in CABG and AVR patients with RIPC	14/05/2013		Benchmark met
10/H0701/117	Clinical Utility of PIGF in pregnancy	24/05/2013	29/05/2013	Benchmark met
12/514/0084	CCRN 2010 - Baxter 261201: PEGylated Recombinant Factor VIII	16/05/2012	20/07/2012	Reasons for delay rest with both sponsor
13/EM/0084 10/H0701/111	in Severe Hemophilia A ERICCA study Version 1.0	16/05/2013 20/05/2013		Benchmark met
10/110/01/111	ENICCA Study Version 1.0	20/05/2013	24/07/2013	benchmark met
12/SC/0434	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	21/05/2013	30/09/2013	Reasons for delay rest with the Sponsor
11/WS/0012	The REMOVAL study	03/06/2013		Benchmark met
_,,	Myocardial Oedema in ST segment elevation myocardial	23,00,2013	, 0., 2013	
13/SW/0082	infarction	28/05/2013	23/07/2013	Benchmark met
, , , , , , , , , , , , , , , , , , , ,	NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with	.,,	.,.,	Delays due to external factors outside the
13/EM/0012	malignant melanoma	15/05/2013		control of the Sponsor and Trust
				·
13/SW/0072	FTY720D2205 (CCRN 2149)	12/06/2013		Reasons for delay rest with the Sponsor
	RESORCE: The regorafenib in patients with hepatocellular			Delays due to external factors outside the
13/LO/0150	carcinoma	11/06/2013		control of the Sponsor and Trust
12/LO/1201	UK Haplo	25/06/2013	14/07/2013	Benchmark met
				Delays due to external factors outside the
12/NW/0367	MCRN177 (BEL114055)	14/06/2013		control of the Sponsor and Trust
	NEOMERO-2 PK and Safety of Meropenem in Infants with			Delays due to external factors outside the
11/LO/1857	Meningitis	26/06/2013	16/01/2014	control of the Sponsor and Trust
	OCTAVE, Ranibizumab in neovascular age-related macular	/ /	0.5/0.5/0.5/0	
13/LO/0520	degeneration(CRFB002A2405)	14/06/2013		Benchmark met
13/NW/0320 13/NW/0321	MCRN235 (WA28117) MCRN234 (WA28118)	24/06/2013 24/06/2013		Benchmark met Benchmark met
12/LO/1876	COBRIM - GO28141	28/06/2013		Benchmark met
12/NW/0641	NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	18/07/2013		Benchmark met
13/SC/0213	ACT IV Study - Protocol CDX110-04	18/07/2013		Benchmark met
13/SC/0171	VX12-809-104 Lumacaftor + Ivacaftor in Cystic Fibrosis	13/08/2013		Benchmark met
12/WA/1064	ZEST	07/08/2013		Reasons for delay rest with the Trust
	Extension study of GS-7977 in patients with HCV infection (GS-			,
12/EE/0400	US-334-0109)	08/08/2013	09/10/2013	Benchmark met
13/WM/0231	SNIFFLE Study	03/09/2013	01/10/2013	Benchmark met
				Delays due to external factors outside the
13/WA/0101	CCRN 2088 (Pneumonia)	22/08/2013		control of the Sponsor and Trust
				Delays due to external factors outside the
13/NW/0464	CCRN 2274 (Liver failure)	30/08/2013	21/01/2014	control of the Sponsor and Trust
		00/00/00/0	0=10110011	Delays due to external factors outside the
10/H1202/81	TREC	09/09/2013	0//01/2014	control of the Sponsor and Trust
44 /514 /0227	N/ICA tetrangenia in ademotel annualistad annualis	40/00/2042	07/04/2044	Reasons for delay rest with both sponsor
11/EM/0237	IVICA: Intravenous iron in colorectal cancer associated anaemia	10/09/2013	07/04/2014	and irust
12/WA/0345	NeoSCOPE: Neoadjuvant - Study of Chemoradiotherapy in	04/09/2013	00/10/2012	Benchmark met
12/WA/0345 12/YH/0404	OesoPhagEal Cancer CE-MARC 2	23/09/2013		Benchmark met
13/EM/0331				Benchmark met
1-0/ LIVI/ UUUT		23/09/2012		LOCIOTATION NAMED
11/SS/0100	PA for the management of fatigue in RA (FRAPA)	23/09/2013 24/09/2013		
11/SS/0100	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision	23/09/2013 24/09/2013		Benchmark met
11/SS/0100 12/EE/0257	PA for the management of fatigue in RA (FRAPA)		01/10/2013	
	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C	24/09/2013	01/10/2013	Benchmark met
	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047)	24/09/2013	01/10/2013 24/10/2013	Benchmark met
12/EE/0257	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF	24/09/2013 24/09/2013	01/10/2013 24/10/2013 11/11/2013	Benchmark met Benchmark met
12/EE/0257 13/EM/0254	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	24/09/2013 24/09/2013 23/09/2013	01/10/2013 24/10/2013 11/11/2013	Benchmark met Benchmark met Benchmark met
12/EE/0257 13/EM/0254	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	24/09/2013 24/09/2013 23/09/2013	01/10/2013 24/10/2013 11/11/2013 15/10/2013	Benchmark met Benchmark met Benchmark met Benchmark met
12/EE/0257 13/EM/0254 13/EE/0263	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302) MASTER II Trial	24/09/2013 24/09/2013 23/09/2013 20/09/2013	01/10/2013 24/10/2013 11/11/2013 15/10/2013	Benchmark met Benchmark met Benchmark met Benchmark met Delays due to external factors outside the
12/EE/0257 13/EM/0254 13/EE/0263 13/LO/0418	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302) MASTER II Trial SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	24/09/2013 24/09/2013 23/09/2013 20/09/2013 23/08/2013 25/09/2013	01/10/2013 24/10/2013 11/11/2013 15/10/2013 22/10/2013	Benchmark met Benchmark met Benchmark met Benchmark met Delays due to external factors outside the control of the Sponsor and Trust
12/EE/0257 13/EM/0254 13/EE/0263 13/LO/0418	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302) MASTER II Trial SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	24/09/2013 24/09/2013 23/09/2013 20/09/2013 23/08/2013	01/10/2013 24/10/2013 11/11/2013 15/10/2013 22/10/2013	Benchmark met Benchmark met Benchmark met Benchmark met Delays due to external factors outside the control of the Sponsor and Trust Benchmark met Reasons for delay rest with both sponsor and Trust
12/EE/0257 13/EM/0254 13/EE/0263 13/LO/0418 13/SC/0211	PA for the management of fatigue in RA (FRAPA) FOCUS - Fluoxetine Or Control Under Supervision MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302) MASTER II Trial SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228) Adjunctive Clindamycin for Cellulitis: C4C Trial	24/09/2013 24/09/2013 23/09/2013 20/09/2013 23/08/2013 25/09/2013	01/10/2013 24/10/2013 11/11/2013 15/10/2013 22/10/2013 28/01/2014	Benchmark met Benchmark met Benchmark met Benchmark met Delays due to external factors outside the control of the Sponsor and Trust Benchmark met Reasons for delay rest with both sponsor

Ethics		Project Site R&D	Date of First Patient	
Committee Ref	Project Title	Submission	Consented	Benchmark Met or Reason for Delay
	·			Delays due to external factors outside the
11/NW/0075	Lung ART	09/10/2013		control of the Sponsor and Trust
	Oral vs Intravenous Antibiotics (OVIVA) for Bone and Joint			
13/SC/0016	Infection	10/10/2013	21/10/2013	Benchmark met
	MCRN 2419: KOGNITO (Kuvan®'s effect on the cOGNITion of			
13/LO/0945	children with phenylketOnuria)	24/09/2013	28/01/2014	Reasons for delay rest with the Sponsor
12/LO/0639	A-PREDICT	11/10/2013		Reasons for delay rest with the Sponsor
10/H0802/13	The HOT-KID study	04/11/2013	20/03/2014	Reasons for delay rest with the Trust
				Delays due to external factors outside the
12/LO/1319	UKALL60+	05/11/2013		control of the Sponsor and Trust
	(RAFT) Reducing Arthritis Fatigue - clinical Teams using cognitive-			
13/EE/0310	behavioural approaches	13/11/2013	07/01/2014	Benchmark met
				Delays due to external factors outside the
12/LO/1109	PROMPTS	20/11/2013		control of the Sponsor and Trust
	ROCHE PHASE I SINGLE ASCENDING DOSE Study of RO6867461			
13/NE/0294	in wAMD	18/11/2013	10/01/2014	Benchmark met
13/YH/0136	CCRN 2173 (AI Liver Decompensation)	16/10/2013		Reasons for delay rest with the Sponsor
GTAC185	PROSTVAC	18/10/2013	28/01/2014	Reasons for delay rest with the Sponsor
	ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2			
	Trial of SGI-110 and Carboplatin in Subjects with Platinum-			
13/LO/0615	Resistant Recurrent Ovarian Cancer	22/11/2013	18/02/2014	Reasons for delay rest with the Sponsor
12/NW/0513	SALVO	13/12/2013	24/02/2014	Reasons for delay rest with the Sponsor
				Delays due to external factors outside the
13/YH/022	MCI-196-E16	10/04/2013		control of the Sponsor and Trust
11/MRE00/1	EORTC 26091 (TAVAREC)	16/12/2013		Benchmark met
13/LO/1283	MO 28037 - TAMIGA	16/12/2013		Benchmark met
11/SW/0036	TABLET	18/01/2014		Benchmark met
13/SC/0452	VX12-809-105 CF Rollover study	23/01/2014	14/03/2014	Benchmark met
	NCRN492 - NEMO-MEK162 vs Dacarzabine in NRAS mutation			
13/LO/0720	postive melanoma patients	21/01/2014		Benchmark met
13/WA/0269	CCRN 771 (Endometriosis-related pain)	30/01/2014	11/03/2014	Benchmark met
				Reasons for delay rest with both sponsor
12/EE/0071	CCRN 923 (Ascites)	20/11/2013		and Trust
10/H0306/61	Platelets for Neonatal Transfusion Study	17/02/2014		70 days not yet reached
	Continuation Study of Prophylactic BAX 855 in PTP with			
14/NW/0001	Haemophilia A	17/02/2014		Benchmark met
13/NW/0002	CCRN 1073 (Thoracic aortic surgery)	06/02/2014	05/03/2014	Benchmark met
4.4.4.4.4.004.0	Developing a new drug to treat infants hospitalised with RSV	24/02/2044		
14/WM/0013	infection	24/02/2014		70 days not yet reached
13/SW/0300	CoolXenon3	21/02/2014		Benchmark met
13/YH/0229	GO2	19/02/2014		70 days not yet reached
12/10/0161	MAESTRO: Macitentan in Eisenmenger Syndrome AC-055-305	20/02/20:		70 days a structure as a least
13/LO/0161	(CCRN 2104)	28/02/2014		70 days not yet reached
11/41/0001	SAPROCAN: Saracatnib and docetaxel in met, cast-ref prostate	10/02/2011		70 days not yet reached
11/AL/0081	cancer	10/03/2014		70 days not yet reached
14/EM/0001	TREND	11/03/2014		70 days not yet reached
42/55/0277	M12-813: Elagolix in Premenopausal Women with Heavy	42/02/20:		70 days a structure as a least
13/EE/0377	Menstrual Bleeding Associated with Uterine Fibroids	13/03/2014		70 days not yet reached
13/WS/0304	EVARREST™ (The Fibrin Pad CV Phase III Study)	17/03/2014		70 days not yet reached
12/5/4/0495	FFFECT Efficiency of Flutinosana/F	11/02/2011		70 days not yet reached
13/SW/0186	EFFECT - Efficacy of Fluticasone/Formoterol in COPD Treatment	11/03/2014		70 days not yet reached
12/LO/1078	MUK five	20/03/2014 11/03/2014		70 days not yet reached
13/YH/0020	MCRN222 (MCI-196-E14)	11/03/2014	1	70 days not yet reached

No of days to First Patient Consented

Projects have been colour coded to identify length of time from submission of an application to first patient consented Key: BLACK - No recruitment > 70 days , RED+ - Recruited > 100 days , RED - Recruited 71 - 100 days , GREEN - Recruited <70 days



Reasons for Delays in First Patient Consented

Internal delay: delay due to UH Bristol Trust issue

Both internal and external delay: contributing factors for delay from both UH Bristol and external party, e.g. contract review External delay sponsor: examples include delayed site initiation visits, green light visit.

External delay protocol design: protocol stipulates that very rare patient group/low recruitment or other protocol design which means site is unable to reasonably expect to recruit within 70 days.

External delay University: any University involvement contributing to the delay- e.g. contract review

External delay other Trust: a delay caused by an external Trust e.g. reviewing contracts, delaying initiation.

External delay other: any other delays which fall outside the above categories and are due to factors external to the Trust.

